重组人VEGF-C His标签VEGF-C|Recombinant Human VEGF-C
产品说明书
FAQ
COA
已发表文献
Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors. VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4. Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1. Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis. VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes.
Product Properties
|
Synonyms |
Flt4 ligand; Flt4-L; vascular endothelial growth factor C; Vascular endothelial growth factor-related protein; VEGFC; VEGF-C; VRPFLT4 ligand DHM |
|
Accession |
P49767 |
|
Source |
HEK293 Cells-derived human VEGF-C, Thr103-Arg227 with a C-terminal polyhistidine tag. |
|
Molecular Weight |
The recombinant mature form of human VEGFC consists of 136 amino acids and has a predicted molecular mass of 15.5 kDa. In SDS-PAGE under reducing conditions, it migrates with an apparent molecular mass of 22.5 kDa due to glycosylation. |
|
Tag |
His |
|
Physical Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
|
Purity |
> 95% by SDS-PAGE. |
|
Biological Activity |
1. Measured by its binding ability in a functional ELISA. Immobilized VEGF C-his at2μg/mL(100 μL/well) can bind VEGFR3 hFc, the EC50 of VEGFR3 hFc is 2-15 ng/mL. |
|
Endotoxin |
< 1.0 EU per 1μg of the protein by the LAL method. |
|
Formulation |
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. Normally 5% – 8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
|
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
Shipping and Storage
The products are shipped with ice pack and can be stored at -20 ℃ for 1 year.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 °C under sterile conditions after reconstitution.
Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.
Cautions
- Avoid repeated freeze-thaw cycles.
- For your safety and health, please wear lab coats and disposable gloves for operation.
- For research use only.
HB221025
Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors. VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4. Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1. Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis. VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes.
Product Properties
|
Synonyms |
Flt4 ligand; Flt4-L; vascular endothelial growth factor C; Vascular endothelial growth factor-related protein; VEGFC; VEGF-C; VRPFLT4 ligand DHM |
|
Accession |
P49767 |
|
Source |
HEK293 Cells-derived human VEGF-C, Thr103-Arg227 with a C-terminal polyhistidine tag. |
|
Molecular Weight |
The recombinant mature form of human VEGFC consists of 136 amino acids and has a predicted molecular mass of 15.5 kDa. In SDS-PAGE under reducing conditions, it migrates with an apparent molecular mass of 22.5 kDa due to glycosylation. |
|
Tag |
His |
|
Physical Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
|
Purity |
> 95% by SDS-PAGE. |
|
Biological Activity |
1. Measured by its binding ability in a functional ELISA. Immobilized VEGF C-his at2μg/mL(100 μL/well) can bind VEGFR3 hFc, the EC50 of VEGFR3 hFc is 2-15 ng/mL. |
|
Endotoxin |
< 1.0 EU per 1μg of the protein by the LAL method. |
|
Formulation |
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. Normally 5% – 8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
|
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
Shipping and Storage
The products are shipped with ice pack and can be stored at -20 ℃ for 1 year.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 °C under sterile conditions after reconstitution.
Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.
Cautions
- Avoid repeated freeze-thaw cycles.
- For your safety and health, please wear lab coats and disposable gloves for operation.
- For research use only.
HB221025
暂无内容
暂无内容
